X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (73) 73
index medicus (60) 60
oncology (56) 56
male (46) 46
middle aged (41) 41
aged (35) 35
immunology (33) 33
female (29) 29
cancer (24) 24
adult (22) 22
melanoma (21) 21
dendritic cells (19) 19
immunotherapy (18) 18
care and treatment (17) 17
dendritic cells - immunology (17) 17
animals (16) 16
antineoplastic agents - therapeutic use (16) 16
killer cells, natural - immunology (16) 16
metastasis (15) 15
prostate cancer (15) 15
treatment outcome (15) 15
metastatic melanoma (14) 14
ipilimumab (13) 13
aged, 80 and over (12) 12
chemotherapy (12) 12
disease-free survival (12) 12
expression (12) 12
melanoma - immunology (12) 12
mice (12) 12
melanoma - drug therapy (10) 10
survival (10) 10
vaccination (10) 10
cancer research (9) 9
carcinoma (9) 9
combined modality therapy (9) 9
docetaxel (9) 9
in-vivo (9) 9
neoplasm metastasis (9) 9
research (9) 9
t cells (9) 9
activation (8) 8
differentiation (8) 8
kidney neoplasms - drug therapy (8) 8
lymphocyte activation (8) 8
lymphocytes (8) 8
melanoma - pathology (8) 8
neoplasm staging (8) 8
prostatic neoplasms, castration-resistant - pathology (8) 8
responses (8) 8
t-cells (8) 8
t-lymphocyte subsets - immunology (8) 8
t-lymphocytes - immunology (8) 8
urology & nephrology (8) 8
analysis (7) 7
antibodies, monoclonal - therapeutic use (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
cytokines (7) 7
double-blind (7) 7
drug therapy (7) 7
flow cytometry (7) 7
hematology, oncology and palliative medicine (7) 7
indoles - therapeutic use (7) 7
kaplan-meier estimate (7) 7
neoplasms - immunology (7) 7
pyrroles - therapeutic use (7) 7
retrospective studies (7) 7
survival analysis (7) 7
taxoids - therapeutic use (7) 7
urology (7) 7
vaccines (7) 7
allergy and immunology (6) 6
alpha-galactosylceramide (6) 6
antigen-presenting cells (6) 6
antigens (6) 6
antineoplastic agents - adverse effects (6) 6
carcinoma, renal cell - drug therapy (6) 6
cd1d (6) 6
cell line (6) 6
cell line, tumor (6) 6
clinical trials (6) 6
cytokines - biosynthesis (6) 6
dendritic cells - metabolism (6) 6
interferon-alpha (6) 6
lymph nodes - immunology (6) 6
mitoxantrone (6) 6
nkt cells (6) 6
prostatic neoplasms, castration-resistant - drug therapy (6) 6
t-lymphocytes, cytotoxic - immunology (6) 6
tumor (6) 6
abiraterone (5) 5
antigens, cd1d (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
cabazitaxel (5) 5
cancer vaccines - immunology (5) 5
cancer vaccines - therapeutic use (5) 5
cd8-positive t-lymphocytes - immunology (5) 5
cells, cultured (5) 5
colony-stimulating factor (5) 5
cytotoxicity (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2010, Volume 363, Issue 8, pp. 711 - 723
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 7, pp. 700 - 712
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 08/2017, Volume 44, Issue 8, pp. 1319 - 1327
Journal Article
Lancet Oncology, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 509 - 517
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 2018, Volume 36, Issue 24, pp. 2504 - 2513
Purpose: Testicular cancer (TC) treatment increases risk of subsequent malignant neoplasms (SMNs). It is unknown whether changes in TC treatment over time have... 
MORTALITY | CHILDHOOD-CANCER | MANAGEMENT | CISPLATIN | NEOPLASMS | ONCOLOGY | RADIOTHERAPY | SURVIVORS | 2ND CANCERS | CHEMOTHERAPY | MOLECULAR-MECHANISMS
Journal Article
Cancer Immunology Immunotherapy, ISSN 0340-7004, 04/2016, Volume 65, Issue 4, pp. 405 - 415
Impaired immune effector functions in the melanoma sentinel lymph node (SLN) may allow for early metastatic events. In an effort to determine the optimal way... 
CpG | Regulatory T cells | Sentinel lymph node | GM-CSF | Immunotherapy | Melanoma | OLIGODEOXYNUCLEOTIDES | MYELOID DENDRITIC CELLS | TOLERANCE | IMMUNOLOGY | PF-3512676 | METASTATIC MELANOMA | RESPONSES | ONCOLOGY | LATENCY-ASSOCIATED PEPTIDE | ERADICATION | Single-Blind Method | T-Lymphocyte Subsets - immunology | Oligodeoxyribonucleotides - administration & dosage | Lymph Nodes - pathology | Skin Neoplasms - drug therapy | Dendritic Cells - immunology | Humans | Middle Aged | Male | Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use | T-Lymphocytes, Regulatory - immunology | Dose-Response Relationship, Drug | CD4-CD8 Ratio | T-Lymphocyte Subsets - drug effects | Killer Cells, Natural - immunology | Adult | Dendritic Cells - drug effects | Female | Lymph Nodes - drug effects | Adaptive Immunity - immunology | Oligodeoxyribonucleotides - therapeutic use | Skin Neoplasms - pathology | Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage | Skin Neoplasms - immunology | Treatment Outcome | Lymph Nodes - immunology | Melanoma - pathology | T-Lymphocytes, Regulatory - drug effects | Adaptive Immunity - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - immunology | Melanoma - drug therapy | Aged | Killer Cells, Natural - drug effects | Sentinel Lymph Node Biopsy | Neoplasm Staging | Metastasis | T cells | Original
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2017, Volume 23, Issue 19, pp. 5679 - 5686
Journal Article